Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptist Gallwitz

Showing results (31-40 of 126) with videos related to

Pageof 13
Sort By:
Current Opinion in Endocrinology, Diabetes, and Obesity|December 26, 2015
Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advancesBaptist Gallwitz
Innere Medizin (Heidelberg, Germany)|August 21, 2024
[Drug therapy of type-2-diabetes-is metformin dispensable now?]Baptist Gallwitz
The Review of Diabetic Studies : RDS|May 10, 2007
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventionsBaptist Gallwitz
The Review of Diabetic Studies : RDS|May 12, 2007
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretinsBaptist Gallwitz
MMW Fortschritte Der Medizin|August 9, 2021
[Novel indications for GLP-1-analogues and SGLT-2-inhibitors: when should a general practitioner prescribe these agents?]Baptist Gallwitz
Handbook of Experimental Pharmacology|April 13, 2011
GLP-1 agonists and dipeptidyl-peptidase IV inhibitorsBaptist Gallwitz
Expert Opinion on Investigational Drugs|April 20, 2011
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapyBaptist Gallwitz
Frontiers in Endocrinology|July 6, 2019
Clinical Use of DPP-4 InhibitorsBaptist Gallwitz
Drug Safety|January 20, 2010
Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitusBaptist Gallwitz
Vascular Health and Risk Management|June 22, 2007
Review of sitagliptin phosphate: a novel treatment for type 2 diabetesBaptist Gallwitz
Pageof 13

Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Current Opinion in Endocrinology, Diabetes, and Obesity|December 26, 2015
Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advancesBaptist Gallwitz
Innere Medizin (Heidelberg, Germany)|August 21, 2024
[Drug therapy of type-2-diabetes-is metformin dispensable now?]Baptist Gallwitz
The Review of Diabetic Studies : RDS|May 10, 2007
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventionsBaptist Gallwitz
The Review of Diabetic Studies : RDS|May 12, 2007
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretinsBaptist Gallwitz
MMW Fortschritte Der Medizin|August 9, 2021
[Novel indications for GLP-1-analogues and SGLT-2-inhibitors: when should a general practitioner prescribe these agents?]Baptist Gallwitz
Handbook of Experimental Pharmacology|April 13, 2011
GLP-1 agonists and dipeptidyl-peptidase IV inhibitorsBaptist Gallwitz
Expert Opinion on Investigational Drugs|April 20, 2011
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapyBaptist Gallwitz
Frontiers in Endocrinology|July 6, 2019
Clinical Use of DPP-4 InhibitorsBaptist Gallwitz
Drug Safety|January 20, 2010
Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitusBaptist Gallwitz
Vascular Health and Risk Management|June 22, 2007
Review of sitagliptin phosphate: a novel treatment for type 2 diabetesBaptist Gallwitz
Pageof 13